1. Diagnosis and Treatment of Hypophosphatasia.
- Author
-
Seefried L, Genest F, Hofmann C, Brandi ML, and Rush E
- Subjects
- Humans, Enzyme Replacement Therapy methods, Immunoglobulin G, Recombinant Fusion Proteins, Hypophosphatasia diagnosis, Hypophosphatasia therapy, Hypophosphatasia genetics, Alkaline Phosphatase therapeutic use, Alkaline Phosphatase genetics
- Abstract
Hypophosphatasia (HPP) is a rare inherited metabolic disorder characterized by deficient activity of tissue-nonspecific alkaline phosphatase (TNAP) caused by variants in the ALPL gene. Disease manifestations encompass skeletal hypomineralization with rickets and lung hypoplasia, vitamin B6-dependent seizures, craniosynostosis, and premature loss of deciduous teeth. The clinical presentation can comprise failure to thrive with muscular hypotonia, delayed motor development, and gait disturbances later in childhood. In adults, pseudofractures are a characteristic indicator of severely compromised enzyme activity, but non-canonical symptoms like generalized musculoskeletal pain, weakness, and fatigue, frequently accompanied by neuropsychiatric and gastrointestinal issues are increasingly recognized as key findings in patients with HPP. The diagnosis is based on clinical manifestations in combination with persistently low alkaline phosphatase (ALP) activity, elevated levels of ALP substrates, specifically inorganic pyrophosphate (PPi), pyridoxal 5'-phosphate (PLP) or urine phosphoethanolamine (PEA), and genetic confirmation of a causative ALPL variant. Considering the wide range of manifestations, treatment must be multimodal and tailored to individual needs. The multidisciplinary team for comprehensive management of HPP patients should include expertise to ensure disease state metabolic and musculoskeletal treatment, dental care, neurological and neurosurgical surveillance, pain management, physical therapy, and psychological care. Asfotase alfa as first-in-class enzyme replacement therapy (ERT) for HPP has been shown to improve survival, rickets, and functional outcomes in severely affected children, but further research is needed to refine how enzyme replacement can also address emerging manifestations of the disease. Prospectively, further elucidating the pathophysiology behind the diverse clinical manifestations of HPP is instrumental for improving diagnostic concepts, establishing novel means for substituting enzyme activity, and developing integrative, multimodal care., Competing Interests: Declarations. Disclosure: L. Seefried has received honoraria for lectures and advice from Amgen, AM-Pharma, Alexion, Biomarin, Chiesi, GedeonRichter, GSK/Haleon, Inozyme, Ipsen, KyowaKirin, Medi, Novartis, Stadapharm, Theramex, and Ultragenyx and research grants to the Institution (University of Würzburg) from Alexion, Chiesi, Kyowa Kirin. F. Genest has received honoraria for lectures from Abbvie, Alexion, and Lilly. E.T. Rush has received consulting fees from Alexion AstraZeneca Rare Disease, Ultragenyx Pharmaceuticals, Kyowa Kirin, Inozyme Pharma, Ipsen SA, Be Bio, Inc, honoraria for lectures from Alexion AstraZeneca Rare Disease, Kyowa Kirin, and Inozyme Pharma, research support from Alexion AstraZeneca Rare Disease, and Ultragenyx Pharmaceuticals. Human and Animal Rights: This overview manuscript does not report original human or animal data., (© 2025. The Author(s).)
- Published
- 2025
- Full Text
- View/download PDF